Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells $10,797,975.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $479.91, for a total transaction of $10,797,975.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Michael Benkowitz also recently made the following trade(s):

• On Monday, November 24th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $473.66, for a total transaction of $10,657,350.00.
• On Monday, November 17th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $470.43, for a total transaction of $10,584,675.00.
• On Monday, November 10th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $452.07, for a total value of $10,171,575.00.
• On Monday, November 3rd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $429.25, for a total value of $9,658,125.00.
• On Monday, October 27th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $417.50, for a total value of $9,393,750.00.
• On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $427.41, for a total value of $9,616,725.00.
• On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $440.35, for a total value of $9,907,875.00.
• On Monday, October 6th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $450.24, for a total value of $10,130,400.00.
• On Monday, September 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $421.80, for a total transaction of $9,490,500.00.
• On Monday, September 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $416.35, for a total transaction of $9,367,875.00.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $484.10 on Friday. The company has a 50 day moving average price of $451.78 and a two-hundred day moving average price of $366.63. The company has a market capitalization of $20.85 billion, a PE ratio of 18.34, a PEG ratio of 4.78 and a beta of 0.86. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $492.62.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same period last year, the firm posted $6.39 earnings per share. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. On average, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Ratings Changes

UTHR has been the subject of several recent analyst reports. Wells Fargo & Company increased their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Bank of America increased their target price on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. UBS Group raised their target price on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Royal Bank Of Canada upped their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Finally, Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $505.00.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Chung Wu Investment Group LLC acquired a new position in United Therapeutics during the second quarter worth $29,000. WealthCollab LLC lifted its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its stake in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. SVB Wealth LLC bought a new position in shares of United Therapeutics in the 1st quarter valued at about $32,000. Finally, Wilmington Savings Fund Society FSB increased its position in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.